EpiCept Corp (EPCT.PK)

EPCT.PK

About

EpiCept Corporation (EpiCept) is a specialty pharmaceutical company focused on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. It focuses on topically delivered analgesics targeting peripheral nerve receptors and on cancer therapies. Its oncology compounds include... (more)

Buy/Sell

No analyst recommendations are available for EPCT.PK.

» Analyst Consensus

Overall

Beta:	1.49
Market Cap (Mil.):	$6.12
Shares Outstanding (Mil.):	112.22
Dividend:	--
Yield (%):	--

Financials

	EPCT.PK	Industry	Sector
P/E (TTM):	--	35.66	35.83
EPS (TTM):	-0.08	--	--
ROI:	--	19.36	18.72
ROE:	--	20.07	19.54

Latest News about EPCT.PK

» More EPCT.PK News

Competitors

	Price	Change
Pfizer Inc. (PFE.N)	$28.96	-0.29
Endo Health Solutions Inc (ENDP.OQ)	$34.38	+1.07
Abbott Laboratories (ABT.N)	$36.59	-0.24
Bayer AG (BAYGn.DE)	€83.79	-1.01
Bayer AG (BAYE.F)	--	--
Sanofi SA (SASY.PA)	€84.50	-0.12
Eli Lilly & Co. (LLY.N)	$55.90	-0.04
Bristol Myers Squibb Co. (BMY.N)	$43.30	+0.53
Bristol Myers Squibb Co. (BMY_p.N)	$567.60	0.00
Amgen, Inc. (AMGN.OQ)	$105.63	+0.66

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
EpiCept Corp Provider: S&P Capital IQ Factual Report	$127.00 Buy
EpiCept Corp: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
ValuEngine Detailed Valuation Report for EPCT Provider: ValuEngine, Inc.	$127.00 Buy
Wright Investors Service Comprehensive Report for Epicept Corporation Provider: Wright Reports	$460.00 Buy
EPICEPT CORPORATION - DEAL TO FORM IMMUNE PHARMA Provider: Edison Investment Research	$10.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.